Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/01/31 17:53:17」(JST)

wiki en

Streptozotocin (Streptozocin, STZ, Zanosar®) is a naturally occurring chemical that is particularly toxic to the insulin-producing beta cells of the pancreas in mammals. It is used in medicine for treating certain cancers of the Islets of Langerhans and used in medical research to produce an animal model for hyperglycemia in a large dose as well as Type 1 diabetes with multiple low doses.

Usage

Streptozotocin is approved by the U.S. Food and Drug Administration (FDA) for treating metastatic cancer of the pancreatic islet cells. Since it carries a substantial risk of toxicity and rarely cures the cancer, its use is generally limited to patients whose cancer cannot be removed by surgery. In these patients, streptozotocin can reduce the tumor size and reduce symptoms (especially hypoglycemia due to excessive insulin secretion by insulinomas).^[1] A typical dose is 500 mg/m²/day by intravenous injection, for 5 days, repeated every 4-6 weeks.

Due to its high toxicity to beta cells, in scientific researches, streptozotocin has also been long used for inducing insulitis and diabetes on experimental animals.^[2]

Mechanism

Streptozotocin is a glucosamine-nitrosourea compound. As with other alkylating agents in the nitrosourea class, it is toxic to cells by causing damage to the DNA, though other mechanisms may also contribute. DNA damage induces activation of poly ADP-ribosylation, which is likely more important for diabetes induction than DNA damage itself.^[3] Streptozotocin is similar enough to glucose to be transported into the cell by the glucose transport protein GLUT2, but is not recognized by the other glucose transporters. This explains its relative toxicity to beta cells, since these cells have relatively high levels of GLUT2.^[4]^[5]

History

Streptozotocin was originally identified in the late 1950s as an antibiotic.^[6] The drug was discovered in a strain of the soil microbe Streptomyces achromogenes by scientists at the drug company Upjohn (now part of Pfizer) in Kalamazoo, Michigan. The soil sample in which the microbe turned up had been taken from Blue Rapids, Kansas, which can therefore be considered the birthplace of streptozotocin. Upjohn filed for patent protection for the drug in August 1958 and U.S. Patent 3,027,300 was granted in March 1962.

In the mid-1960s streptozotocin was found to be selectively toxic to the beta cells of the pancreatic islets, the cells that normally regulate blood glucose levels by producing the hormone insulin. This suggested the drug's use as an animal model of diabetes,^[7]^[8] and as a medical treatment for cancers of the beta cells.^[9] In the 1960s and 1970s the National Cancer Institute investigated streptozotocin's use in cancer chemotherapy. Upjohn filed for FDA approval of streptozotocin as a treatment for pancreatic islet cell cancer in November 1976, and approval was granted in July 1982. The drug was subsequently marketed as Zanosar.

Streptozotocin is now marketed by the generic drug company Sicor (Teva).

References

^ Brentjens R, Saltz L (2001). "Islet cell tumors of the pancreas: the medical oncologist's perspective". Surg Clin North Am 81 (3): 527–42. doi:10.1016/S0039-6109(05)70141-9. PMID 11459269.
^ Rossini, A. A.; Like, A. A. A; Chick, W. L.; Appel, M. C.; Cahill Jr, G. F. (1977). "Studies of streptozotocin-induced insulitis and diabetes". Proceedings of the National Academy of Sciences of the United States of America 74 (6): 2485–2489. doi:10.1073/pnas.74.6.2485. PMC 432197. PMID 142253.
^ Szkudelski T (2001). "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas.". Physiol Res 50 (6): 537–46. PMID 11829314.
^ Wang Z, Gleichmann H (1998). "GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice". Diabetes 47 (1): 50–6. doi:10.2337/diabetes.47.1.50. PMID 9421374.
^ Schnedl WJ, Ferber S, Johnson JH, Newgard CB (1994). "STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells". Diabetes 43 (11): 1326–33. doi:10.2337/diabetes.43.11.1326. PMID 7926307.
^ Vavra JJ, Deboer C, Dietz A, Hanka LJ, Sokolski WT (1959). "Streptozotocin, a new antibacterial antibiotic". Antibiot Annu 7: 230–5. PMID 13841501.
^ Mansford KR, Opie L (1968). "Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan". Lancet 1 (7544): 670–1. doi:10.1016/S0140-6736(68)92103-X. PMID 4170654.
^ Rerup CC (1970). "Drugs producing diabetes through damage of the insulin secreting cells". Pharmacol Rev 22 (4): 485–518. PMID 4921840.
^ Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW (1968). "Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin". Lancet 2 (7574): 895–8. doi:10.1016/S0140-6736(68)91058-1. PMID 4176152.

External links

U.S. Patent 3,027,300
FDA drug details

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 転移性膵神経内分泌腫瘍および低分化胃腸膵管神経内分泌腫瘍：腫瘍増殖をコントローするための全身療法およびホルモン分泌過剰の症状 metastatic pancreatic neuroendocrine tumors and poorly differentiated gastroenteropancreatic neuroendocrine carcinomas systemic therapy options to control tumor growth and symptoms of hormone hypersecretion
2. 転移性の胃腸系神経内分泌腫瘍（カルチノイド）：腫瘍増殖およびホルモン過剰分泌による症状を管理するための全身治療の選択肢 metastatic gastrointestinal neuroendocrine carcinoid tumors systemic therapy options to control tumor growth and symptoms of hormone hypersecretion
3. 副腎皮質癌の治療 treatment of adrenocortical carcinoma
4. 進行性膵外分泌癌に対する化学療法 chemotherapy for advanced exocrine pancreatic cancer
5. VIP産生腫瘍：臨床的特徴、診断、およびマネージメント vipoma clinical manifestations diagnosis and management

English Journal

Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies.

Verheyen A, Peeraer E, Lambrechts D, Poesen K, Carmeliet P, Shibuya M, Pintelon I, Timmermans JP, Nuydens R, Meert T.SourceDepartment of Neuroscience, Janssen Research & Development, A Division of Janssen Pharmaceutica NV, B-2340 Beerse, Belgium.
Neuroscience.Neuroscience.2013 Aug 6;244:77-89. doi: 10.1016/j.neuroscience.2013.03.050. Epub 2013 Apr 11.
Besides its prominent role in angiogenesis, the vascular endothelial growth factor (VEGF) also exerts important protective effects on neurons. In particular, mice expressing reduced levels of VEGF suffer from late-onset motor neuron degeneration, whereas VEGF delivery significantly delays motor neur
PMID 23583762

The generation of pancreatic β-cell spheroids in a simulated microgravity culture system.

Tanaka H, Tanaka S, Sekine K, Kita S, Okamura A, Takebe T, Zheng YW, Ueno Y, Tanaka J, Taniguchi H.SourceDepartment of Regenerative Medicine, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan.
Biomaterials.Biomaterials.2013 Jul;34(23):5785-91. doi: 10.1016/j.biomaterials.2013.04.003. Epub 2013 May 2.
Islet transplantation can induce a substantial improvement in the treatment of type 1 diabetes mellitus. However, the clinical application of islet transplantation is severely limited by the shortage of donor organs. It is thus essential to improve the engraftment rate to achieve the expected outcom
PMID 23642538

Inhibition of instant blood-mediated inflammatory responses by co-immobilization of sCR1 and heparin on islets.

Luan NM, Iwata H.SourceDepartment of Reparative Materials, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-Cho, Shogoin, Sakyo-Ku, Kyoto 606-8507, Japan.
Biomaterials.Biomaterials.2013 Jul;34(21):5019-24. doi: 10.1016/j.biomaterials.2013.03.041. Epub 2013 Apr 9.
Intraportal transplantation of islets of Langerhans is followed by marked islet loss, mainly caused by instant blood-mediated inflammatory responses (IBMIR). We previously developed a method of co-immobilizing sCR1 and heparin on islets. Here we examined whether this process could reduce islet loss
PMID 23578554

Japanese Journal

薬剤誘発性糖尿病ラットにおける糖尿病発症早期の膀胱機能障害

五十嵐匠,吉澤剛,佐藤克彦
日大医学雑誌 = Journal of Nihon University Medical Association 71(5), 322-328, 2012-10
NAID 40019473197

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin-Nicotinamide-Induced Mildly Diabetic Mice

TAHARA Atsuo,KUROSAKI Eiji,YOKONO Masanori,YAMAJUKU Daisuke,KIHARA Rumi,HAYASHIZAKI Yuka,TAKASU Toshiyuki,IMAMURA Masakazu,QUN Li,TOMIYAMA Hiroshi,KOBAYASHI Yoshinori,NODA Atsushi,SASAMATA Masao,SHIBASAKI Masayuki
Journal of pharmacological sciences 120(1), 36-44, 2012-09-20
NAID 10031071887

Protective effect of herbomineral formulation (Dolabi) on early diabetic nephropathy in streptozotocin-induced diabetic rats

BAIG Mirza A.,GAWALI Vikas B.,PATIL Rajesh R.,NAIK Suresh R.
Journal of natural medicines 66(3), 500-509, 2012-07-20
NAID 10031087806

Related Pictures

★リンクテーブル★

リンク元	「ストレプトゾトシン」「STZ」
拡張検索	「streptozotocin diabetes」

「ストレプトゾトシン」

Streptozotocin
Systematic (IUPAC) name
	2-Deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose
Clinical data
Trade names	Zanosar
MedlinePlus	a684053
Pregnancy; category	US: D (Evidence of risk); ;
Legal status	℞ (Prescription only);
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	17-25%
Metabolism	liver, kidney
Biological half-life	35-40 minutes
Identifiers
CAS Number	18883-66-4
ATC code	L01AD04
PubChem	CID 29327
DrugBank	DB00428
ChemSpider	27273
UNII	5W494URQ81
KEGG	C07313
ChEBI	CHEBI:9288
ChEMBL	CHEMBL450214
Chemical data
Formula	C8H15N3O7
Molar mass	265.221 g/mol
	SMILES CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O ;
	InChI InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1 ; Key:ZSJLQEPLLKMAKR-GKHCUFPYSA-N ;
(what is this?) (verify)